Ingredients
Option A — Warfarin (Coumadin)
- 2–10 mg/day Warfarin sodium tablets (dose adjusted to INR 2.0–3.0)
- Every 1–4 weeks INR blood test monitoring (weekly at start, monthly when stable)
- Consistent Vitamin K intake (leafy greens, broccoli — don't eliminate, keep steady)
Option B — Eliquis (Apixaban)
- 5 mg twice daily Apixaban tablets (2.5 mg BID if 2+ of: age ≥80, weight ≤60 kg, Cr ≥1.5)
- Annually Kidney function check (no routine INR monitoring needed)
Option C — Xarelto (Rivaroxaban)
- 20 mg once daily Rivaroxaban tablets (take with evening meal for AFib)
- 15 mg daily Reduced dose (if CrCl 15–50 mL/min)
- Annually Kidney and liver function (no INR monitoring needed)
Required for All Options
- Ongoing Bleeding risk assessment (HAS-BLED score)
- As needed Drug interaction review (NSAIDs, antibiotics, antifungals)
Method
Determine Your Indication
Identify why anticoagulation is needed: atrial fibrillation (most common — reduces stroke risk by 65%), deep vein thrombosis, pulmonary embolism, or mechanical heart valve. Your indication determines which options are even on the table — warfarin is the only choice for mechanical valves.
Calculate Bleeding Risk
Run the HAS-BLED score: hypertension (1), abnormal kidney/liver function (1–2), stroke history (1), bleeding history (1), labile INR (1), elderly >65 (1), drugs/alcohol (1–2). Score ≥3 = high bleeding risk. This doesn't mean you skip anticoagulation — it means you monitor more aggressively.
Match Drug to Patient Profile
Choose Warfarin if: mechanical valve, severe kidney disease (CrCl <15), cost is primary concern ($4/month generics), or patient can commit to INR monitoring. Choose Eliquis if: lowest bleeding risk data matters (ARISTOTLE trial — 31% less major bleeding vs warfarin), twice-daily dosing is acceptable. Choose Xarelto if: once-daily convenience preferred, active cancer (some data), or patient is already on it and stable.
Establish the Monitoring Protocol
Warfarin: target INR 2.0–3.0 for most indications. Check INR weekly until stable (2 consecutive in range), then every 2–4 weeks. DOACs: check kidney function at baseline and annually (more often if CrCl <60). Neither Eliquis nor Xarelto requires routine INR or anti-Xa monitoring.
Plan the Bridge and Exit Strategy
If switching from warfarin to a DOAC: stop warfarin, start DOAC when INR falls below 2.0. If switching from DOAC to warfarin: overlap with warfarin until INR ≥2.0, then stop DOAC. Never stop abruptly — missing even 2 doses of a DOAC can allow clot formation. Know the reversal agents: Vitamin K + FFP/PCC for warfarin, idarucizumab (Praxbind) for Xarelto/Eliquis, andexanet alfa for Eliquis/Xarelto.
Reassess at 30, 90, and 365 Days
At 30 days: any bleeding events? Dose adjustments needed? At 90 days: repeat kidney function, reassess indication. At 1 year: full bleeding risk recalculation. Ongoing AFib patients should have annual CHA₂DS₂-VASc reassessment — your stroke risk changes as you age and accumulate comorbidities.
Tips & Pro Tricks
- Warfarin timing matters: Take it at the same time every day — evening is standard. If you miss a dose, take it as soon as you remember the same day. Never double up.
- DOACs and food: Xarelto 15 mg and 20 mg must be taken with food for proper absorption. Eliquis can be taken with or without food. Warfarin should be taken on an empty stomach for consistent absorption.
- The NSAID trap: Ibuprofen and naproxen increase bleeding risk with ALL anticoagulants. Use acetaminophen (Tylenol) instead. Aspirin doubles bleeding risk — only combine with anticoagulants if cardiologist specifically orders it.
- Missing a DOAC dose: Eliquis: take it within 6 hours of missed dose, then resume normal schedule. Xarelto: take it immediately, then resume next day. Never take a double dose of either.
- Carry an alert card: Wear a medical alert bracelet or carry a card stating your anticoagulant, dose, and prescribing doctor. ER physicians need this information immediately for trauma decisions.
Variations
The Budget Protocol
Warfarin at $4/month generic with home INR monitoring (CoaguChek devices, ~$400/year strips). Best for uninsured or high-deductible patients. Trade-off: time commitment for INR checks and dietary consistency. Works well for organized, routine-oriented patients.
The Low-Bleeding Priority
Eliquis 5 mg BID — based on the ARISTOTLE trial (n=18,201), it's the only DOAC that showed statistically significant superiority over warfarin in both stroke prevention AND major bleeding. Best for elderly patients, those with prior GI bleeds, or anyone where bleeding risk is the primary concern.
The Compliance-First Approach
Xarelto 20 mg once daily with the evening meal. Single daily dosing improves adherence in patients who struggle with twice-daily regimens. Best for busy professionals, patients on many medications, or those who've missed BID doses before. Caveat: missing one daily dose leaves a longer gap in protection.
The Mechanical Valve Protocol
Warfarin ONLY — target INR 2.5–3.5 for aortic valves, 3.0–4.0 for mitral valves. DOACs are contraindicated with mechanical valves (the RE-ALIGN trial was stopped early due to increased thromboembolism and bleeding with dabigatran). This is non-negotiable per current guidelines.
The Kidney Compromise
For CrCl 15–30: reduced-dose Xarelto (15 mg daily) or warfarin. For CrCl <15 or dialysis: warfarin is the only safe option — DOACs are not recommended. Check kidney function every 3–6 months in this population, not annually.
Why This Formula Works
Blood thinners don't actually thin your blood — they interrupt the clotting cascade at specific points. Warfarin blocks vitamin K–dependent clotting factors (II, VII, IX, X) in the liver, taking 3–5 days for full effect. DOACs (Eliquis and Xarelto) directly inhibit Factor Xa, the final common pathway before thrombin generation, working within hours.
The key difference: warfarin affects multiple factors broadly (requiring monitoring), while DOACs target a single factor precisely (predictable dosing). A 2019 meta-analysis in the Journal of the American College of Cardiology (n=81,000+) confirmed DOACs reduce intracranial hemorrhage by 50% compared to warfarin across all four approved agents. For AFib patients, the annual stroke risk without anticoagulation is ~5% — with treatment, it drops to ~1.5%.